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Introduction
Fatigue is a distressing and pervasive symptom, 
reported in up to 80% of patients with chronic 
inflammatory disorders, such as rheumatoid 
arthritis, systemic lupus erythematosus or chronic 
liver disease.1–3 This issue is also relevant to gas-
trointestinal (GI) diseases. Patients with inflam-
matory bowel diseases (IBD), such as ulcerative 
colitis (UC) or Crohn’s disease,4–9 and irritable 
bowel syndrome (IBS)10–12 frequently report 
severe fatigue. In both IBD and IBS, those report-
ing fatigue often have reduced quality of life,6,13,14 
and it has also been shown that psychological fac-
tors, such as depression or anxiety, are predictors 
for increased levels of fatigue in patients with 
IBS.15
Microscopic colitis (MC), often described as 
either collagenous (CC) or lymphocytic colitis 
(LC) is a less well-recognized form of IBD but is 
also associated with impaired quality of life.16,17 
Given that patients with MC experience chronic 
diarrhoea, similar to patients with IBD and those 
with diarrhoea-predominant IBS, it is probable 
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that fatigue will also be a pertinent issue in MC. 
However, data assessing levels of fatigue in MC 
are sparse. In one previous cross-sectional study, 
the symptom of fatigue was more prevalent in 
both LC and CC compared with controls,16 but 
this was not assessed using a validated fatigue 
questionnaire. This study also demonstrated an 
increased prevalence of fatigue even among those 
classed as having quiescent MC, based on self-
reported absence of diarrhoea.16 Similar findings 
have been reported in classical IBD, where fatigue 
was reported in comparable numbers of patients 
with both active and inactive disease.4,5
It has therefore been hypothesized that fatigue in 
patients with IBD may relate to the presence of 
concomitant functional symptoms.18,19 There are 
data to support the fact that patients with IBD in 
remission, assessed using faecal calprotectin, but 
who have ongoing IBS-type symptoms, may have 
marked psychological comorbidity and impaired 
quality of life.20 This study was therefore designed 
to examine patient characteristics associated with 
fatigue in patients with a histological diagnosis of 
MC, using a validated fatigue assessment tool.
Materials and methods
Participants and setting
Participants were identified from a cohort of 
adult patients with a new histological diagnosis of 
MC at the Leeds Teaching Hospitals Trust, 
United Kingdom, between January 2010 and 
December 2015. Patients were invited to partici-
pate once survival status was confirmed, a diag-
nosis of cognitive impairment excluded, and a 
valid contact address obtained. Those with a 
known prior histologic diagnosis of MC were 
excluded. Potentially eligible participants were 
sent study documents, including a questionnaire 
and written consent form by post, and initial non-
responders received a second postal questionnaire. 
The study was approved by the local research eth-
ics committee (Yorkshire and The Humber, Leeds 
West, United Kingdom) in January 2016, and 
the postal surveys took place between June 2016 
and February 2017.
Diagnosis of microscopic colitis
A diagnosis of CC was made in the presence of a 
subepithelial collagen band of ⩾10 µm in thickness, 
with evidence of diffuse chronic inflammation, and 
a diagnosis of LC using a threshold of >20 intra-
epithelial lymphocytes per 100 epithelial cells, also 
with evidence of diffuse chronic inflammation, but 
no thickening of the subepithelial collagen band. In 
patients where the recorded pathology diagnosis did 
not clearly specify the subtype of MC, we recorded 
a diagnosis of ‘MC, not otherwise specified 
(MC-NOS)’ as, at our centre, the diagnoses of 
incomplete CC or LC are not made. It has previ-
ously been demonstrated that there is little interob-
server variability in the diagnosis of MC.21
Clinical and demographic data
All participants were asked to provide the follow-
ing demographic data: sex, age, ethnicity, marital 
status, educational level, tobacco and alcohol use, 
and weight (in kilograms) and height (in metres), 
which were used to calculate body mass index 
(BMI). We also asked participants to complete a 
checklist of medications previously reported as 
being implicated in the development of MC,22 
and to respond to questions regarding the pres-
ence of common autoimmune diseases associated 
with MC,23 including coeliac disease, thyroid dis-
ease, rheumatoid arthritis, psoriasis, autoimmune 
hepatitis, and type 1 diabetes. Patients were asked 
to report their stool frequency, as well as if they 
had ongoing GI symptoms that they attributed to 
MC. The latter was recorded as a dichotomized 
outcome as either ‘yes’ or ‘no’.
IBS-type symptoms, according to the Rome III 
criteria,24 included abdominal pain or discomfort 
occurring at least 3 days per month over the past 
3 months, with the onset of discomfort at least 
6 months previously, associated with two or more 
of the following: an improvement of pain or dis-
comfort with the passage of stool, more or less 
frequent stools, or looser or harder stools.
To assess for the presence of either anxiety or 
depression, participants were asked to complete 
the validated 14-item Hospital Anxiety and 
Depression Scale (HADS) questionnaire.25 This 
includes seven questions screening for the pres-
ence of anxiety, and another seven questions for 
depression. Each question is scored from 0 to 3, 
resulting in a maximum potential score of 21 for 
anxiety or depression, separately. The severity of 
anxiety and depression symptoms was then 
graded according to three categories: normal 
(total depression or anxiety scores 0–7), border-
line abnormal (8–10), and abnormal (⩾11).
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In order to assess for the presence of somatiza-
tion, we used the Patient Health Questionnaire 
15 (PHQ-15), a validated questionnaire enquir-
ing about the presence of 15 specific somatic 
symptoms occurring within the previous 
4 weeks.26 Symptoms were graded into three lev-
els of severity; ‘not bothered at all’ (scored as 0), 
‘bothered a little’ (scored as 1), or ‘bothered a lot’ 
(scored as 2), giving a total possible score of 30. 
The severity of somatization was categorized into 
high (total score ⩾15), medium (10–14), low (5–
9), and minimal (⩽4) levels, as has been previ-
ously recommended.27
Finally, the validated medical outcomes study 
36-item Short Form (SF-36) score was used to 
assess health-related quality of life.28 The 36 
questions are grouped into eight domains: physi-
cal functioning, role limitations due to physical 
health, role limitations due to emotional health, 
energy or fatigue, emotional well-being, social 
functioning, pain, and general health. Participants 
were asked to score each question from 0 to 100, 
with higher scores indicating more favourable 
quality of life.
Assessment of fatigue severity and impact
Participants were asked to complete a scoring tool 
known as the Inflammatory Bowel Disease Fatigue 
Assessment Scale (IBD-F). This was designed 
using cohorts of patients with either Crohn’s dis-
ease or UC,29 and has been validated for use in 
IBD.30,31 It is composed of two sections, with 
scores for each calculated separately. The first sec-
tion (fatigue severity component) is designed as a 
baseline assessment of presence and severity of 
fatigue, and includes five questions measured on a 
Likert scale (from 0–4) with a maximum score of 
20. The second section (fatigue impact compo-
nent) includes 30 questions, again measured on a 
Likert scale (from 0–4) with a maximum score of 
120, and assesses the impact of fatigue on the 
patient’s activities of daily living. Patients can 
score 0 in either section, indicating the absence of 
fatigue or impact on activities of daily living.
Statistical analysis
Mean levels of fatigue severity and impact were 
compared according to baseline demographic 
characteristics, including medications and coex-
istent autoimmune disease, the presence of IBS-
type symptoms, presence or absence of abnormal 
HADS anxiety or depression scores, and presence 
or absence of high levels of somatization using a 
student’s t test. The relationship between fatigue 
severity and impact scores and age, BMI, HADS 
scores, PHQ-15 scores, and SF-36 scores were 
assessed using Pearson’s correlation coefficient. A 
two-tailed p value of <0.01 was considered to be 
statistically significant for all analyses, due to 
multiple comparisons. All statistical analyses were 
performed using SPSS for Windows version 21.0 
(SPSS Inc., Chicago, IL, USA).
Results
Postal questionnaires were distributed to 478 
potentially eligible patients, all of whom were 
diagnosed with MC over the 6-year study period. 
Of 157 (32.8%) responders, 6 patents were found 
to have a prior histological diagnosis of MC and 
were therefore excluded (Figure 1). In total, 129 
(85.4%) of 151 eligible responders completed the 
IBD-F questionnaire fully, and were included in 
Figure 1. Flow chart of patients recruited into the 
study.
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the analysis. In terms of subtype, 69 patients 
(53.5%) had CC, 50 (38.8%) had LC, and 10 
(7.8%) had MC-NOS. Only a few patients 
reported previous autoimmune diseases including 
coeliac disease (n = 10), thyroid disease (n = 19), 
and rheumatoid arthritis (n = 8), but none 
reported type 1 diabetes, autoimmune liver dis-
ease, or psoriasis. Comparing characteristics of 
responders to the questionnaire with nonrespond-
ers revealed no significant differences in MC sub-
type or sex, but there was a trend towards 
responders being older [mean age 68.0 years 
(standard deviation, SD 9.8) versus 65.4 (SD 
12.6), p = 0.03].
Fatigue severity and its associated features in 
microscopic colitis
For the fatigue severity assessment component, 
the mean score in all patients was 8.2 (SD ± 4.9), 
and the median score was 9 [interquartile range 
(IQR) 4–34]. Mean fatigue severity scores accord-
ing to patient demographics, clinical data, pres-
ence or absence of abnormal anxiety or depression 
scores, and presence or absence of high levels of 
somatization are provided in Table 1. There were 
trends towards patients using proton pump inhib-
itors (PPIs) reporting more severe fatigue. 
Patients with IBS-type symptoms had signifi-
cantly higher mean fatigue severity scores, and 
higher scores were also significantly associated 
with presence of abnormal anxiety and depression 
scores, and high levels of somatization (p < 0.001 
for all). Of note, mean fatigue severity scores in 
those reporting ongoing symptoms that they felt 
were related to their MC were not significantly 
higher. There were significant positive correla-
tions between HADS scores and PHQ-15 scores 
and fatigue severity scores, and significant nega-
tive correlations between quality-of-life scores 
across all domains of the SF-36 and fatigue severity 
(Table 2).
Fatigue impact and its associated features in 
microscopic colitis
For the fatigue impact-on-daily-life component, 
the mean score in all patients was 25.0 (SD ± 
26.5), and the median score was 16 (IQR 4–35). 
Details of mean fatigue impact scores according 
to patient demographics, clinical data, presence 
or absence of abnormal anxiety or depression 
scores, and presence or absence of high levels of 
somatization are provided in Table 1. Patients 
with IBS-type symptoms, smokers, those taking 
PPIs, those with abnormal anxiety or depression 
scores, and those with high levels of somatization 
had significantly higher fatigue impact scores. 
There was also a trend towards higher mean 
fatigue impact scores in those with a higher stool 
frequency. Again, there were significant positive 
correlations between HADS scores and PHQ-15 
scores and fatigue impact scores, and significant 
negative correlations between quality-of-life 
scores across all domains of the SF-36 and fatigue 
impact (Table 2).
Discussion
This cross-sectional survey has demonstrated that 
patients with MC often report high levels of 
fatigue severity and impact as assessed by the 
IBD-F self-assessment tool. Patients with abnor-
mal anxiety and depression scores and high levels 
of somatization reported higher mean fatigue 
severity scores, and a greater impact on their daily 
lives. Fatigue severity and impact scores were also 
significantly higher among those patients with 
IBS-type symptoms, but not among those with 
ongoing GI symptoms that they attributed to 
their diagnosis of MC. There was also a trend 
towards higher mean fatigue impact scores in 
those with a higher stool frequency. Finally, 
higher levels of both the impact and severity of 
fatigue led to reduced quality of life, as measured 
by the SF-36.
To our knowledge, this is the first study to use a 
specific fatigue assessment questionnaire to 
examine the severity of fatigue in patients with 
MC and to study the impact of fatigue in such a 
population. We attempted to contact all patients 
with a new histological diagnosis of MC diag-
nosed in a secondary care setting over a 6-year 
period, and therefore our findings are likely to be 
generalizable to other patients with MC in usual 
clinical practice. Data on psychological health, 
somatization, and quality of life were collected 
using validated questionnaires. We also collected 
data on functional GI symptoms, and self-
reported symptoms suggestive of active MC, 
allowing us to assess whether fatigue was related 
to possible disease activity, or rather just GI 
symptom-reporting per se.
There are some limitations to this study. We 
lacked a control group of individuals without 
MC in order to assess levels of fatigue compared 
JS Kane, AJ Irvine et al.
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p value* Mean fatigue 
impact score (SD)
p value*
Type of MC  
Collagenous colitis 8.3 (5.0) 23.1 (27.6)  
Lymphocytic colitis 7.5 (4.8) 0.37 25.6 (25.0) 0.61
Sex  
Female 8.4 (4.8) 26.3 (26.8)  
Male 7.3 (5.0) 0.26 20.8 (25.8) 0.32
Married or cohabiting  
Yes 7.7 (4.6) 22.0 (23.3)  
No 8.9 (5.2) 0.18 30.5 (31.1) 0.08
University graduate  
Yes 6.7 (4.3) 18.2 (17.7)  
No 8.7 (5.0) 0.03 27.6 (28.8) 0.07
Current smoker  
Yes 11.0 (5.0) 46.1 (32.3)  
No 7.8 (4.8) 0.03 22.7 (24.9) 0.002
Using PPIs  
Yes 9.2 (5.1) 33.6 (29.8)  
No 7.2 (4.4) 0.02 17.3 (20.5) <0.001
Using NSAIDs  
Yes 7.9 (5.3) 25.7 (27.4)  
No 8.3 (4.7) 0.71 24.7 (26.2) 0.83
Using ranitidine  
Yes 9.6 (5.0) 32.0 (26.1)  
No 7.9 (4.8) 0.15 23.7 (26.5) 0.20
Using aspirin  
Yes 8.3 (4.8) 27.0 (24.5)  
No 8.1 (4.9) 0.81 24.4 (27.3) 0.63
Using selective serotonin reuptake inhibitors  
Yes 9.7 (5.2) 35.4 (29.0)  
No 7.8 (4.7) 0.08 22.6 (25.5) 0.03
Using statins  
Yes 8.3 (4.6) 25.1 (24.1)  
No 8.1 (5.0) 0.87 25.0 (27.8) 0.03
(Continued)




p value* Mean fatigue 
impact score (SD)
p value*
Autoimmune thyroid disease  
Yes 7 (5.2) 20.7 (24.1)  
No 8.4 (4.8) 0.26 25.0 (27.8) 0.44
Rheumatoid arthritis  
Yes 9.8 (5.6) 36.5 (31.2)  
No 8.1 (4.8) 0.34 24.3 (26.1) 0.59
Coeliac disease  
Yes 8.0 (5.0) 29.4 (32.4)  
No 9.6 (3.5) 0.33 24.7 (26.1) 0.59
Rome III IBS-type symptoms  
Present 10.4 (4.6) 38.2 (30.4)  
Absent 7.0 (4.6) <0.001 17.9 (21.2) <0.001
Stool frequency  
1–3 times per day 6.9 (4.0) 17.0 (19.6)  
4–6 times per day 8.8 (4.7) 26.3 (26.3)  
7–9 times per day 6.3 (4.0) 17.0 (27.6)  
>10 times per day 9.6 (6.1) 0.06 38.6 (31.1) 0.01
Described ongoing symptoms of MC  
Present 8.4 (4.6) 28.6 (27.4)  
Absent 7.8 (5.2) 0.52 20.7 (25.0) 0.09
Abnormal anxiety scores  
Present 10.8 (4.6) 42.6 (30.7)  
Absent 6.5 (4.3) <0.001 14.1 (16.1) <0.001
Abnormal depression scores  
Present 13.8 (3.1) 61.1 (26.0)  
Absent 6.7 (4.1) <0.001 15.1 (15.5) <0.001
High levels of somatization  
Present 13.9 (4.3) 67.3 (26.4)  
Absent 7.2 (4.3) <0.001 18.2 (19.3) <0.001
* All comparisons made using student t tests.
IBS, irritable bowel syndrome; MC, microscopic colitis; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump 
inhibitor; SD, standard deviation.
Table 1. (Continued)
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with a background population. We also used the 
Rome III criteria for IBS,24 which have been 
superseded by the Rome IV criteria,32 because 
our study was designed and conducted prior to 
the publication of the latest iteration of these cri-
teria. A further potential limitation is the recruit-
ment of patients diagnosed with MC as long ago 
as 2010. This may have led to recall bias affecting 
the accuracy of reporting of clinical information, 
such as medication use. However, all of the vali-
dated questionnaires we administered, including 
the IBD-F and Rome III criteria, required con-
temporaneous answers. Participants were also 
asked to complete several different question-
naires, each with multiple questions, and this may 
have been burdensome, perhaps explaining why 
22 patients did not fully complete the IBD-F. All 
participants were sent postal questionnaires, and 
this may have introduced volunteer bias in to our 
study; the implication would be those responding 
may have been intrinsically different to nonre-
sponders. Unfortunately, as we did not have detailed 
demographic information on all patients with 
MC prior to study commencement, we were 
unable to compare all characteristics of respond-
ers and nonresponders, so we are uncertain 
whether those who took part are representative of 
the original population of 478 eligible patients. 
However, an analysis based on age, sex, and MC 
subtype did not reveal any significant differences 
between responders and nonresponders. It is 
unlikely that patients with higher levels of fatigue 
were more likely to take part, as this was only one 
aspect of our study, and the participant informa-
tion sheet did not focus specifically on the issue 
of fatigue in MC.
It should also be noted that disease activity was 
not assessed by either a specific MC disease activ-
ity score, or by endoscopic or histologic assess-
ment, as the recently proposed MC disease 
activity index was not published at the time we 
conducted this study.33 Together with the fact 
that the average age of patients was >60 years, 
Table 2. Correlations between age, body mass index, Hospital Anxiety and Depression Scale scores, PHQ-15 
scores, quality-of-life scores, and fatigue severity and impact in patients with microscopic colitis.
Fatigue severity score Fatigue impact score
 R score p value R score p value
Age −0.21 0.02 −0.21 0.02
Body mass index 0.1 0.45 0.15 0.11
Total HADS anxiety score 0.58 <0.001 0.65 <0.001
Total HADS depression score 0.71 <0.001 0.80 <0.001
Total PHQ-15 score 0.69 <0.001 0.71 <0.001
SF-36 physical functioning −0.48 <0.001 −0.58 <0.001
SF-36 role limitations physical health −0.58 <0.001 −0.58 <0.001
SF-36 role limitations emotional health −0.59 <0.001 −0.67 <0.001
SF-36 energy/fatigue −0.76 <0.001 −0.70 <0.001
SF-36 emotional well-being −0.69 <0.001 −0.76 <0.001
SF-36 social functioning −0.70 <0.001 −0.72 <0.001
SF-36 pain −0.54 <0.001 −0.57 <0.001
SF-36 general health −0.66 <0.001 −0.69 <0.001
*All correlations made using Pearson’s correlation coefficient.
HADS, Hospital Anxiety and Depression Scale; PHQ-15, Patient Health Questionnaire 15; SF-36, Short Form 36 health survey.
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this could mean that those reporting higher levels 
of fatigue severity and fatigue impact had either 
active MC, or other unrelated comorbidities that 
contributed to their fatigue, although those with 
symptoms attributable to their MC did not have 
higher mean scores, and there was no significant 
correlation between age and either fatigue impact 
or severity scores. Finally, we should reflect on 
the use of the IBD-F score. This was developed in 
patients with ‘classical’ IBD diagnoses of UC or 
Crohn’s disease, rather than MC. The benefits of 
this scale include the robust, patient-led develop-
ment, which was well received by participants in 
the derivation study,29 and the fact that it has 
been shown to be comparable to other fatigue 
assessment tools.30 However, further work is 
needed to confirm the validity of this tool in MC.
Previous data on the prevalence of fatigue in MC 
are limited. Nyhlin and colleagues conducted a 
cross-sectional survey in patients with both CC 
and LC, using recent watery diarrhoea as a marker 
of disease activity, and assessing for the presence 
of fatigue using a specific question within their 
administered questionnaire.16 They suggested 
that fatigue was more prevalent in those felt to 
have active disease, but even those with inactive 
disease were twice as likely to report fatigue, com-
pared with the background population. Although 
we cannot compare our data to a background 
population without MC, our use of a structured 
questionnaire allowed us to assess both the sever-
ity and impact of fatigue. We have also shown 
that the severity and impact of fatigue was not sig-
nificantly affected by the presence of ongoing 
symptoms suggestive of active MC. This finding 
is supported by evidence of a high prevalence of 
fatigue in patients with both inactive UC and 
Crohn’s disease,13,19 and although an increase in 
both the severity and impact of fatigue has been 
observed in patients with IBD, this did not cor-
relate with objective markers of disease activity, 
such as faecal calprotectin or haemoglobin.34
Making a direct comparison between patients 
with MC and classical IBD is difficult, due to the 
absence of a comparable biomarker for disease 
activity, and widely accepted clinical disease 
activity indices are lacking. In terms of data on 
IBD-F scores in patients with UC or Crohn’s, 
Vestergaard and colleagues reported median 
fatigue scores of 9 (IQR 5–11) and 21 (IQR 4–34) 
for fatigue severity or impact, respectively,31 and 
Ratnakumaran and colleagues reported mean 
fatigue severity scores of 11.5 (SD 3.0) in UC and 
12.9 (3.6) in Crohn’s, and mean fatigue impact 
scores of 52.0 (28.7) and 53.5 (22.9) in UC and 
Crohn’s, respectively.34 However, stratification of 
either median or mean levels of fatigue severity or 
impact has not been performed. Some studies in 
patients with classical IBD have provided data 
concerning the impact of fatigue on health-related 
quality of life. One study that used clinical disease 
activity indices demonstrated that patients with 
inactive IBD and fatigue also had significant 
impairment of quality of life, based on the SF-36 
scoring system.13 The greatest impact was seen in 
the domains relating to role limitations in physical 
health and general health in Crohn’s disease, and 
role limitation due to physical health in UC.35 In 
contrast, the significant negative correlations 
between quality-of-life scores and both fatigue 
severity and impact we observed were across all 
domains of the SF-36.
A remaining uncertainty relates to the aetiology of 
fatigue in those with quiescent ‘classical’ IBD or 
MC. Piche and colleagues assessed a cohort of 
patients with quiescent Crohn’s disease, report-
ing that almost 50% met criteria for IBS accord-
ing to the Rome III criteria, and that these patients 
had greater impairments in quality of life, higher 
rates of depression and higher levels of fatigue.19 
More recent data, using faecal calprotectin as a 
biomarker for disease activity, have shown that 
patients with quiescent IBD who meet Rome III 
criteria for IBS report increased levels of anxiety, 
depression, somatization and impaired quality of 
life.20 Other authors have concluded that the 
presence of concomitant IBS-type symptoms, in 
those with quiescent IBD, might be a key factor in 
the development of fatigue.18 Similarly, in our 
study, IBS-type symptoms were significantly 
associated with higher mean fatigue severity and 
impact scores. Although we should note the limi-
tations of our study, particularly in determining if 
participants were suffering from recurrent or 
active MC, there was no such association demon-
strated for symptoms suggestive of ongoing MC 
activity. Furthermore, there may be a role for 
low-grade inflammation or chronic immune acti-
vation in the development of fatigue, which is dis-
tinct from active MC,36,37 although we did not 
observe an association with specific autoimmune 
diseases in our study cohort. In contrast, given the 
observed association of fatigue with psychological 
comorbidity, our results suggest that central 
effects occurring due to brain–gut axis activation, 
JS Kane, AJ Irvine et al.
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rather than mucosal inflammation and disease 
activity, or somatoform-type behaviour, may be 
involved in the aetiology of fatigue in MC.
In summary, to our knowledge, this study repre-
sents the first attempt to examine factors associ-
ated with fatigue severity and impact in MC. It is 
clear that, regardless of the aetiology of fatigue in 
patients with a prior diagnosis of MC, coexistent 
anxiety, depression or somatization are associated 
with higher levels of fatigue severity, with a sig-
nificant impact on patients’ lives, and detrimental 
effects on quality of life. Future prospective stud-
ies of fatigue in MC that help to determine the 
severity and impact of fatigue at diagnosis, after 
treatment, and in the longer term, are required. 
Furthermore, there is a growing interest in devel-
oping strategies to target fatigue in both UC and 
Crohn’s disease,38 and our data would suggest 
that the design of such intervention studies in 
patients with MC may also be required.
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